JESSICA ENTREKIN: Open Payments
NPI 1609217876 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,835 in 103 payments from 23 companies in 2025. Trend: 2023 $1,292 · 2024 $2,050 · 2025 $1,835
Food & beverage: $1,835
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $490 |
| ARGENX US, INC. | 4 | $125 |
| Neurocrine BioSciences, Inc. | 4 | $116 |
| ACADIA Pharmaceuticals Inc | 5 | $110 |
| Janssen Biotech, Inc. | 4 | $106 |
| Novartis Pharmaceuticals Corporation | 6 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Neurelis, Inc. | 5 | $89 |
| Merz Pharmaceuticals, LLC | 4 | $89 |
| UCB, Inc. | 2 | $79 |
Products named: QULIPTA, UBRELVY, INGREZZA, NUPLAZID, KESIMPTA, VYVGART, REXULTI, VALTOCO.
Industry payments across AL — which companies pay providers there.
